Page 1

Thyretain® - Thyroid Stimulating Immunoglobulin Reporter BioAssay Thyroid Stimulating Immunoglobulins (TSI) are linked to an autoimmune thyroid disorder called Graves’ disease1. In this disease, the TSI bind to the thyroid stimulating hormone (TSH) receptors (TSHR) of the thyroid gland, causing an over-production of thyroid hormones. This can lead to a number of different symptoms, making the initial diagnosis of thyroid disorders difficult.2 However, the specific detection of TSI in conjunction with other clinical determinations can be used for differential diagnosis of Graves’ disease. Once diagnosed, the disease has a variety of treatment options.3

Diagnostic Hybrids’ Thyretain specifically detects TSI in a user-friendly format. • Specific, sensitive and reproducible test results • Simplified cell culture techniques utilizing DHI frozen cell culture technology • Use of whole serum eliminates the need for IgG purification, saving time and money • Results in 3 to 4 hours, after cell culture is prepared, assures a quick turnaround time in the lab With a procedure for easy handling, a patented testing technology, specific TSI detection and quick turnaround time, Thyretain offers a superior product coupled with accurate results that improve patient care and laboratory workflow.

Function of a CHO Mc4 Cell

A genetically engineered cell line for the specific detection of TSI. - As shown above, Thyretain utilizes a Chinese hamster ovary cell line engineered to express chimeric human TSH receptors and a ­­cAMPinduced luciferase reporter gene (CHO Mc4). The specificity and simplicity of Thyretain allows the user to generate fast, reliable results.

References 1 Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. 2000. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid stimulating antibody and thyrotropin binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 10:891-896. 2. Godfrey, J. (2004) Toward Optimal Health: The Experts Discuss Thyroid Disfunction. Journal of Women’s Health, Vol. 13 Issue 2, p. 141-146. 3 Gittoes, NJL, Franklyn, JA. 1998. Hyperthyroidism: Current Treatment Guidelines. Drugs 55:543-553.

A Quidel Company

© 2010 Quidel Corporation. All rights reserved. For More Information, Contact Us

www.dhiusa.com

(866) 344-3477


Thyretain Product Codes Catalog Code 40-25000.v2 Thyretain TSI Reporter BioAssay capable of testing 25 plates Includes: Thyretain FreshFrozenCells® and Control Set (1), Thyretain Media Set (1), Luciferase Assay Reagent Set (10) 40-50000.v2 Thyretain TSI Reporter BioAssay capable of testing 50 plates Includes: Thyretain FreshFrozenCells® and Control Set (1), Thyretain Media Set (2), Luciferase Assay Reagent Set (20)

Recommended Protocol Gelatin treat in the inner 48 wells of a black, clear-bottom, 96 multi-well plate Dilute 1 vial of CHO Mc4 FreshFrozenCells® in 5-mL Thyretain Growth Medium and seed the treated wells

Individual Component 40-E2610.v2 Luciferase Assay Reagent Set

Incubate cells for 15 to 18 hours

Prepare 1/11 dilutions of controls and specimens

Treat cells with prepared controls and specimens

Incubate cells for 3 hours

Lyse cells for 10 minutes and measure luminescence

Specimen ≥ 140% of the reference control

Specimen < 140% of the reference control

Specimen is “Positive”

Specimen is “Negative”

A Quidel Company

© 2010 Quidel Corporation. All rights reserved. For More Information, Contact Us

www.dhiusa.com

(866) 344-3477 MKT0056v2010AUG11

/MKT0056en_Thyretain_SaleSheet._V2010MAR16  

http://www.dhiusa.com/websites/website1/uploads/documents/MKT0056en_Thyretain_SaleSheet._V2010MAR16.pdf

Read more
Read more
Similar to
Popular now
Just for you